UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.